America First Investment Advisors LLC Buys 12,373 Shares of Pfizer Inc. $PFE

America First Investment Advisors LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 1.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 796,840 shares of the biopharmaceutical company’s stock after purchasing an additional 12,373 shares during the period. Pfizer accounts for about 3.9% of America First Investment Advisors LLC’s investment portfolio, making the stock its 17th biggest position. America First Investment Advisors LLC’s holdings in Pfizer were worth $19,315,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter worth $27,000. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer during the 2nd quarter worth about $29,000. Finally, WPG Advisers LLC bought a new position in Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Trading Up 1.5%

Shares of Pfizer stock opened at $25.45 on Wednesday. The firm’s 50 day simple moving average is $24.82 and its two-hundred day simple moving average is $24.46. The firm has a market capitalization of $144.70 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.